PLK1 and cancer: Moreover, preclinical studies using the combination of PLK1 inhibitors, such as volasertib, along with other agents, such as etoposide, vincristine, vinblastine, vinorelbine, or eribulin, is widely beneficial in treating young patients with rhabdomyosarcoma and other cancers [331,332,333].